Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$91.98
+3.3%		$94.62
$44.42
▼
$151.02
$4.50B0.211.09 million shs1.16 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$25.10
-1.3%		$24.46
$11.92
▼
$27.31
$4.69B1.072.07 million shs1.63 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$42.25
+1.1%		$42.10
$13.69
▼
$48.40
$4.59B0.31.19 million shs1.04 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.83
-1.0%		$3.58
$2.61
▼
$6.55
$1.15B2.163.09 million shs1.70 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+0.70%-1.91%+3.10%-2.58%+73.84%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+1.44%-2.15%+0.99%+47.51%+88.51%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-2.32%-6.60%+8.69%+12.13%+191.08%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-1.53%+2.38%+23.64%+19.44%+26.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$91.98
+3.3%		$94.62
$44.42
▼
$151.02
$4.50B0.211.09 million shs1.16 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$25.10
-1.3%		$24.46
$11.92
▼
$27.31
$4.69B1.072.07 million shs1.63 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$42.25
+1.1%		$42.10
$13.69
▼
$48.40
$4.59B0.31.19 million shs1.04 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.83
-1.0%		$3.58
$2.61
▼
$6.55
$1.15B2.163.09 million shs1.70 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+0.70%-1.91%+3.10%-2.58%+73.84%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+1.44%-2.15%+0.99%+47.51%+88.51%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-2.32%-6.60%+8.69%+12.13%+191.08%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-1.53%+2.38%+23.64%+19.44%+26.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
2.82
Moderate Buy$154.5568.02% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.87
Moderate Buy$34.4237.12% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.82
Moderate Buy$50.3319.13% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.80
Moderate Buy$9.33143.69% Upside

Current Analyst Ratings Breakdown

Latest SANA, DYN, EWTX, and CELC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/20/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$53.00 ➝ $60.00
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$165.00 ➝ $175.00
8/17/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$177.00
8/14/2026
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$155.00
8/14/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$175.00 ➝ $150.00
8/14/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$157.00 ➝ $140.00
8/14/2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$7.00 ➝ $6.00
8/11/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$32.00 ➝ $36.00
(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.93 per shareN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/11/2026 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.85N/AN/AN/AN/A-39.01%-36.96%11/5/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.76N/AN/AN/AN/A-103.02%-39.16%11/5/2026 (Estimated)

Latest SANA, DYN, EWTX, and CELC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
8/11/2026Q2 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1469-$0.13+$0.0169-$0.22N/AN/A
8/6/2026Q2 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.4677-$0.53-$0.0623-$0.53N/AN/A
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
16.24
16.24
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
25.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4048.93 million42.41 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100186.75 million169.08 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60108.60 million85.47 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
380299.36 million223.32 millionOptionable

Recent News About These Companies

Sana Biotechnology to Present at September 2026 Investor Conferences
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354578/0/en/sana-biotechnology-to-present-at-september-2026-investor-conferences.html
16,675,173 Shares in Sana Biotechnology, Inc. $SANA Acquired by BlackRock Inc.
September 1 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-16675173-shares-in-sana-biotechnology-inc-sana-acquired-by-blackrock-inc-2026-09-01/
Canada Pension Plan Investment Board Purchases Shares of 10,218,400 Sana Biotechnology, Inc. $SANA
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-canada-pension-plan-investment-board-purchases-shares-of-10218400-sana-biotechnology-inc-sana-2026-08-28/
Deutsche Bank AG Buys New Stake in Sana Biotechnology, Inc. $SANA
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-buys-new-stake-in-sana-biotechnology-inc-sana-2026-08-28/
As U.S.-China biotech race heats up, Seattle makes its case to D.C.
August 27, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/as-us-china-biotech-race-heats-up-seattle-makes-its-case-to-dc/ar-AA2b4klV
As US.-China biotech race heats up, Seattle makes its case to DC
August 27, 2026  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/as-us-china-biotech-race-heats-up-seattle-makes-its-case-to-dc/ar-AA2b4klV
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 5.7% Following Analyst Upgrade
August 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30985352
Sana Biotechnology (NASDAQ:SANA) Upgraded at TD Cowen
August 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30985159
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Analysts
August 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30984015
Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7% After Analyst Upgrade
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-shares-up-57-after-analyst-upgrade-2026-08-25/
Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-sana-biotechnology-nasdaq-sana-stock-rating-upgraded-by-td-cowen-2026-08-25/
Bank of America Corp DE Has $8.49 Million Stock Position in Sana Biotechnology, Inc. $SANA
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-849-million-stock-position-in-sana-biotechnology-inc-sana-2026-08-25/
Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention
August 21, 2026  |  kalkinemedia.comK
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-inc-nasdaqsana-given-average-rating-of-moderate-buy-by-analysts-2026-08-21/
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-nasdaqsana-stock-price-down-62-time-to-sell-2026-08-20/
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% - Still a Buy?
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-nasdaqsana-stock-price-up-89-still-a-buy-2026-08-19/
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)
August 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SANA/pressreleases/3906219/analysts-offer-insights-on-healthcare-companies-fortrea-holdings-inc-ftre-agomab-therapeutics-nv-adr-agmb-and-sana-biotechnology-sana/
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alphabet-inc-makes-new-982-million-investment-in-sana-biotechnology-inc-sana-2026-08-18/
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter?
August 15, 2026  |  kalkinemedia.comK
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bank-of-america-issues-pessimistic-forecast-for-sana-biotechnology-nasdaqsana-stock-price-2026-08-14/
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sana-biotechnology-nasdaqsana-shares-down-53-should-you-sell-2026-08-14/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Autonomous mobile robots carrying storage bins move through an automated factory production line with illuminated blue accents.
3 Robotics Stocks Under $10: Value, Momentum, or Bet?
By Chris Markoch | August 17, 2026
Medical imaging scanner with exposed internal components being assembled in a manufacturing facility with computer workstations.
Inside Teledyne's Bold Bet on the Future of Medical Imaging
By Jeffrey Neal Johnson | August 14, 2026
A rubber stamp reading "Dividends" rests beside a stamped document, stacked coins, and US currency.
3 Closed-End Funds to Maximize Dividend Payments
By Nathan Reiff | August 23, 2026
Celcuity stock logo

Celcuity NASDAQ:CELC

$91.98 +2.92 (+3.28%)
As of 04:00 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$25.10 -0.33 (-1.30%)
As of 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$42.25 +0.48 (+1.15%)
As of 04:00 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$3.83 -0.04 (-1.03%)
As of 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas